Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV
- 1Merck & Co., Inc., Rahway, New Jersey, USA
Abstract
Ulonivirine is a non-nucleoside reverse transcriptase inhibitor in clinical development for once-weekly oral treatment of HIV-1 in combination with islatravir. This open-label, 3-period, Phase 1 study (MK-8507-016, NCT06619678) in adults without HIV evaluated the potential drug-drug interactions (DDIs) between ulonivirine and islatravir. In Period 1, participants received islatravir 2 mg on Day 1. In Period 2, participants received ulonivirine 200 mg on Days 1 and 8. In Period 3, a single dose of islatravir 2 mg was co-administered with ulonivirine 200 mg 7 days after the Day 8 dose in Period 2, followed by four doses of ulonivirine 200 mg once weekly. Thirty-six participants (58% female, 67% White, median age 43 years) were enrolled. Plasma pharmacokinetics of islatravir and ulonivirine were similar with and without coadministration. The 90% CIs for geometric mean ratios of co-administration versus single administration of islatravir (AUC0-168, 1.06 [1.02–1.09]; C168, 1.05 [0.98–1.12]; Cmax, 1.10 [1.02–1.19]) and ulonivirine (AUC0-168, 1.07 [1.05–1.09]; C168, 1.08 [1.04–1.12]; Cmax, 1.03 [0.98–1.07]) were within standard bioequivalence bounds (0.8–1.25). During Period 3 (co-administration with ulonivirine), intracellular ISL-triphosphate AUC0-168, AUC0-inf, Cmax, and C168 were approximately 21%, 15%, 16%, and 10% lower, respectively, compared with ISL alone. These differences may in part reflect variability in peripheral blood mononuclear cell counts. Adverse events, laboratory test results, and other safety parameters were comparable among all three periods. In conclusion, no clinically meaningful DDIs were observed between ulonivirine 200 mg and islatravir 2 mg, supporting continued development of this combination for HIV-1 treatment.
Related
- A Pilot Proof-of-Concept Study to Evaluate the Physiological and Cognitive Impacts of Hericium erinaceus on Healthy Adults
- Doravirine/islatravir (DOR-ISL) as a new once-daily oral single-tablet regimen for human immunodeficiency virus (HIV) treatment: unmet need or paradox of choice?
- An Objective Assessment for Plank Performance in Active Adults With and Without Low Back Pain: A Reliability and Comparison Study
- Daily physical activity on days with and without tennis lessons among adults in beginner and advanced classes
- Dynamic Measures of Glycemia in Relation to Hepatic Features in Adults Without Diabetes
BibTeX
@article{nussbaum2026openlabel,
title = {{Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV}},
author = {Jesse C. Nussbaum and Michelle M. Pham and Ryan Vargo and Yang Liu and Ilias Triantafyllou and Natasha Boyette and Randolph P. Matthews and Marian Iwamoto and Gillian Gillespie},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
month = oct,
doi = {10.1128/aac.00676-26},
url = {https://doi.org/10.1128/aac.00676-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV
AU - Jesse C. Nussbaum
AU - Michelle M. Pham
AU - Ryan Vargo
AU - Yang Liu
AU - Ilias Triantafyllou
AU - Natasha Boyette
AU - Randolph P. Matthews
AU - Marian Iwamoto
AU - Gillian Gillespie
PY - 2026
DA - 2026/10/08
JO - Antimicrobial Agents and Chemotherapy
DO - 10.1128/aac.00676-26
UR - https://doi.org/10.1128/aac.00676-26
AB - Ulonivirine is a non-nucleoside reverse transcriptase inhibitor in clinical development for once-weekly oral treatment of HIV-1 in combination with islatravir. This open-label, 3-period, Phase 1 study (MK-8507-016, NCT06619678) in adults without HIV evaluated the potential drug-drug interactions (DDIs) between ulonivirine and islatravir. In Period 1, participants received islatravir 2 mg on Day 1. In Period 2, participants received ulonivirine 200 mg on Days 1 and 8. In Period 3, a single dose of islatravir 2 mg was co-administered with ulonivirine 200 mg 7 days after the Day 8 dose in Period 2, followed by four doses of ulonivirine 200 mg once weekly. Thirty-six participants (58% female, 67% White, median age 43 years) were enrolled. Plasma pharmacokinetics of islatravir and ulonivirine were similar with and without coadministration. The 90% CIs for geometric mean ratios of co-administration versus single administration of islatravir (AUC0-168, 1.06 [1.02–1.09]; C168, 1.05 [0.98–1.12]; Cmax, 1.10 [1.02–1.19]) and ulonivirine (AUC0-168, 1.07 [1.05–1.09]; C168, 1.08 [1.04–1.12]; Cmax, 1.03 [0.98–1.07]) were within standard bioequivalence bounds (0.8–1.25). During Period 3 (co-administration with ulonivirine), intracellular ISL-triphosphate AUC0-168, AUC0-inf, Cmax, and C168 were approximately 21%, 15%, 16%, and 10% lower, respectively, compared with ISL alone. These differences may in part reflect variability in peripheral blood mononuclear cell counts. Adverse events, laboratory test results, and other safety parameters were comparable among all three periods. In conclusion, no clinically meaningful DDIs were observed between ulonivirine 200 mg and islatravir 2 mg, supporting continued development of this combination for HIV-1 treatment.
SN - 1098-6596
SN - 0066-4804
ER -